Literature DB >> 25705314

Chronic migraine - new treatment options.

Adina Roceanu1, Florina Antochi1, Ovidiu Bajenaru1.   

Abstract

Chronic migraine (CM) is defined as headache occurring more than fifteen days/month for at least three consecutive months, with headache having the clinical features of migraine without aura for at least eight days per month. Recently, new treatment options became available in chronic migraine patients. Topiramate is effective in chronic migraine, in the presence or absence of medication overuse, and/or other migraine prophylaxis. Efficacy of onabotulinumtoxin A as a preventive treatment of chronic migraine has been shown in the PREEMPT studies. Occipital nerve stimulation (ONS) is an invasive treatment for refractory chronic headaches. ONS has encouraging results in refractory chronic migraine patients in commercially funded, multi-centre randomized trials.

Entities:  

Keywords:  chronic migraine; occipital nerve stimulation; onabotulimumtoxin A; topiramate

Year:  2014        PMID: 25705314      PMCID: PMC4316889     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  19 in total

1.  Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy.

Authors:  Paul L Durham; Ryan Cady; Roger Cady
Journal:  Headache       Date:  2004-01       Impact factor: 5.887

2.  Kaplan Award 1998. Epidemiology of chronic daily headache in the general population.

Authors:  J Castillo; P Muñoz; V Guitera; J Pascual
Journal:  Headache       Date:  1999-03       Impact factor: 5.887

3.  The International Classification of Headache Disorders, 3rd edition (beta version).

Authors: 
Journal:  Cephalalgia       Date:  2013-07       Impact factor: 6.292

4.  OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.

Authors:  David W Dodick; Catherine C Turkel; Ronald E DeGryse; Sheena K Aurora; Stephen D Silberstein; Richard B Lipton; Hans-Christoph Diener; Mitchell F Brin
Journal:  Headache       Date:  2010-05-07       Impact factor: 5.887

5.  Prevalence and description of chronic daily headache in the general population in France.

Authors:  Michel Lantéri-Minet; Jean-Paul Auray; Abdelkader El Hasnaoui; Jean-François Dartigues; Gérard Duru; Patrick Henry; Christian Lucas; André Pradalier; Guy Chazot; Anne-Françoise Gaudin
Journal:  Pain       Date:  2003-03       Impact factor: 6.961

6.  Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura.

Authors:  Simon Akerman; Peter J Goadsby
Journal:  Neuroreport       Date:  2005-08-22       Impact factor: 1.837

Review 7.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

8.  Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.

Authors:  Mitchell F Brin; Cynthia L Comella; Joseph Jankovic; Francis Lai; Markus Naumann
Journal:  Mov Disord       Date:  2008-07-30       Impact factor: 10.338

9.  A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.

Authors:  Ninan T Mathew; Sayyed Farhan A Jaffri
Journal:  Headache       Date:  2009 Nov-Dec       Impact factor: 5.887

10.  Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study.

Authors:  Joel R Saper; David W Dodick; Stephen D Silberstein; Sally McCarville; Mark Sun; Peter J Goadsby
Journal:  Cephalalgia       Date:  2010-09-22       Impact factor: 6.292

View more
  1 in total

1.  Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline.

Authors:  Hans-Christoph Diener; Peter Kropp; Thomas Dresler; Stefan Evers; Stefanie Förderreuther; Charly Gaul; Dagny Holle-Lee; Arne May; Uwe Niederberger; Sabrina Moll; Christoph Schankin; Christian Lampl
Journal:  Neurol Res Pract       Date:  2022-08-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.